Retatrutide 10mg

Retatrutide 10 mg – Triple-Agonist Therapy (Phase 3)

🔹 Mechanism of Action

Retatrutide is a first-in-class triple-agonist. It targets three key hormone receptors in the body:

• GLP-1 (glucagon-like peptide-1)

• GIP (glucose-dependent insulinotropic polypeptide)

• Glucagon receptors

This combination may offer several benefits:

• Reduced appetite (GLP-1)

• Increased fat burning and energy use (glucagon)

• Better insulin sensitivity (GIP)

---

🔹 Clinical Trial Results (Phase 2 Study)

In a 24-week study, Retatrutide 10 mg showed strong results compared to Tirzepatide 10 mg:

• Weight loss: 18.2% vs. 14.9% total body weight

• A1c reduction: 1.8% vs. 1.5%

• Waist reduction: 6.2 inches vs. 5.1 inches

• Nausea rate: 32% vs. 28%

These results suggest improved weight loss and metabolic outcomes.

---

🔹 Dosing and Administration

Retatrutide is given as a weekly injection.

Typical dose schedule:

• Weeks 1–4: 2 mg

• Weeks 5–8: 4 mg

• Weeks 9–12: 6 mg

• Weeks 13–16: 8 mg

• Week 17+: 10 mg (maintenance)

How to use:

• Inject under the skin (abdomen or thigh)

• Use the same day each week

• Rotate injection sites to reduce irritation

---

🔹 Key Benefits of Retatrutide peptide buy online

Retatrutide may offer advantages over existing treatments:

Greater weight loss

• Up to 3–5% more weight loss than tirzepatide

• Higher fat loss while preserving lean muscle

Improved metabolic health

• Reduced liver fat

• Increased resting metabolic rate

• Better blood sugar control

Flexible dosing (under study)

• Monthly dosing may be possible in the future

---

🔹 Safety and Side Effects of Retatrutide peptide buy online

Common side effects include:

• Nausea

• Diarrhea

• Mild increase in heart rate

• Injection site reactions

These effects are usually mild and may improve over time.

Important safety concerns:

• Possible thyroid tumor risk (seen in early studies)

• Risk of pancreatitis

Always consult a healthcare provider before use.

---

🔹 Who May Benefit

Retatrutide may be suitable for:

• People with BMI ≥30 (obesity)

• Patients needing significant weight loss (>15%)

• Individuals who did not respond to other GLP-1 therapies

Not recommended for:

• History of thyroid cancer

• Multiple endocrine neoplasia syndrome type 2

• Severe kidney or liver disease

---

🔹 Monitoring During Treatment

Doctors may recommend regular checks, including:

• Weight and BMI tracking

• Blood sugar and metabolic panels

• Thyroid and pancreatic markers

• Heart health monitoring

---

🔹 Cost and Availability

• Expected cost: $1,200–$1,500 per month (if approved)

• Possible uses: obesity, type 2 diabetes, and liver disease

Retatrutide is still under review by the U.S. Food and Drug Administration and is not yet approved.

---

🔹 Comparison With Other Treatments

---

🔹 Ongoing Research

Current Phase 3 studies are exploring:

• Long-term weight loss (72 weeks)

• Heart health outcomes

• Liver disease (NASH) improvements

• Blood pressure and metabolic effects

---

⚠️ Important Note

Retatrutide is an investigational medication and is not yet approved for public use. Approval will depend on ongoing clinical trial results. Retatrutide peptide buy online